Clinical Trial Update: Refralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atrial Flutter [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial comparing Refralon with Amiodarone for cardioversion in patients with paroxysmal atrial fibrillation and atrial flutter has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Flutter
• Paroxysmal Atrial Fibrillation

Drugs mentioned

• Amiodarone (amiodarone)
• Refralon

Snippet

Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | Conditions: Atrial Fibrillation Paroxysmal | Phase 4 | Status: COMPLETED